Polypeptide-N-Acetylgalactosaminyltransferase 14 (GALNT14)
[Edit]GalNac-T10; GalNac-T14; Polypeptide GalNAc transferase 14; Protein-UDP acetylgalactosaminyltransferase 14; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 14
GALNT14 (EC 2.4.1.41) belongs to a large subfamily of glycosyltransferases residing in the Golgi apparatus. GALNT enzymes catalyze the first step in the O-glycosylation of mammalian proteins by transferring N-acetyl-D-galactosamine (GalNAc) to peptide substrates.
The deduced 552-amino acid type II membrane protein has an N-terminal cytoplasmic domain, followed by a transmembrane domain, a stem region, and a catalytic domain. The catalytic domain contains a GT1 motif, a Gal/GalNAc transferase motif, and a ricin-like lectin motif, which is commonly found in GALNT proteins. GALNT14 shares 49.9% amino acid homology with GALNT2.
Organism species: Homo sapiens (Human)
CATALOG NO. | PRODUCT NAME | APPLICATIONS | |
Proteins | n/a | Recombinant Polypeptide-N-Acetylgalactosaminyltransferase 14 (GALNT14) | Recombinant Protein Customized Service Offer |
Antibodies | n/a | Monoclonal Antibody to Polypeptide-N-Acetylgalactosaminyltransferase 14 (GALNT14) | Monoclonal Antibody Customized Service Offer |
n/a | Polyclonal Antibody to Polypeptide-N-Acetylgalactosaminyltransferase 14 (GALNT14) | Polyclonal Antibody Customized Service Offer | |
Assay Kits | n/a | CLIA Kit for Polypeptide-N-Acetylgalactosaminyltransferase 14 (GALNT14) | CLIA Kit Customized Service Offer |
n/a | ELISA Kit for Polypeptide-N-Acetylgalactosaminyltransferase 14 (GALNT14) | ELISA Kit Customized Service Offer |
Organism species: Mus musculus (Mouse)
CATALOG NO. | PRODUCT NAME | APPLICATIONS | |
Proteins | n/a | Recombinant Polypeptide-N-Acetylgalactosaminyltransferase 14 (GALNT14) | Recombinant Protein Customized Service Offer |
Antibodies | n/a | Monoclonal Antibody to Polypeptide-N-Acetylgalactosaminyltransferase 14 (GALNT14) | Monoclonal Antibody Customized Service Offer |
n/a | Polyclonal Antibody to Polypeptide-N-Acetylgalactosaminyltransferase 14 (GALNT14) | Polyclonal Antibody Customized Service Offer | |
Assay Kits | n/a | CLIA Kit for Polypeptide-N-Acetylgalactosaminyltransferase 14 (GALNT14) | CLIA Kit Customized Service Offer |
n/a | ELISA Kit for Polypeptide-N-Acetylgalactosaminyltransferase 14 (GALNT14) | ELISA Kit Customized Service Offer |
Organism species: Rattus norvegicus (Rat)
CATALOG NO. | PRODUCT NAME | APPLICATIONS | |
Proteins | n/a | Recombinant Polypeptide-N-Acetylgalactosaminyltransferase 14 (GALNT14) | Recombinant Protein Customized Service Offer |
Antibodies | n/a | Monoclonal Antibody to Polypeptide-N-Acetylgalactosaminyltransferase 14 (GALNT14) | Monoclonal Antibody Customized Service Offer |
n/a | Polyclonal Antibody to Polypeptide-N-Acetylgalactosaminyltransferase 14 (GALNT14) | Polyclonal Antibody Customized Service Offer | |
Assay Kits | n/a | CLIA Kit for Polypeptide-N-Acetylgalactosaminyltransferase 14 (GALNT14) | CLIA Kit Customized Service Offer |
n/a | ELISA Kit for Polypeptide-N-Acetylgalactosaminyltransferase 14 (GALNT14) | ELISA Kit Customized Service Offer |
- "Cloning and characterization of a novel UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase, pp-GalNAc-T14."Biochem. Biophys. Res. Commun. 300:738-744(2003) [PubMed] [Europe PMC] [Abstract]
- "The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment." Genome Res. 13:2265-2270(2003) [PubMed] [Europe PMC] [Abstract]
- "Complete sequencing and characterization of 21,243 full-length human cDNAs." Nat. Genet. 36:40-45(2004) [PubMed] [Europe PMC] [Abstract]
- "Generation and annotation of the DNA sequences of human chromosomes 2 and 4." Nature 434:724-731(2005) [PubMed] [Europe PMC] [Abstract]
- "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
- "Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab."Clin. Cancer Res. 16:1587-1596(2010) [PubMed] [Europe PMC] [Abstract]